Effect of amylin in various experimental models of gastric ulcer

Eur J Pharmacol. 1997 Aug 6;332(2):209-13. doi: 10.1016/s0014-2999(97)01081-9.

Abstract

Subcutaneous administration of amylin (20-40 micrograms/kg) prevented, in a dose-dependent manner, reserpine- and serotonin-induced gastric damage, but the anti-ulcer effect was not present when lesions were induced by pylorus ligation. The protective effect of amylin was inhibited by pretreatment with capsicin as well as CGRP-(8-37), a calcitonin gene-related peptide (CGRP) and amylin receptor antagonist, and was significantly reduced by domperidone, a dopamine D2 receptor antagonist, or neostigmine, an inhibitor of acetylcholinesterase. Our data suggest that the gastroprotective activity of amylin in some experimental models of gastric ulcers involves capsaicin-sensitive fibers and CGRP receptors. Moreover, the peptide interferes, at least in part, with the dopaminergic and parasympathetic systems.

MeSH terms

  • Amyloid / administration & dosage
  • Amyloid / therapeutic use*
  • Animals
  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / therapeutic use*
  • Calcitonin Gene-Related Peptide / pharmacology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Humans
  • Injections, Subcutaneous
  • Islet Amyloid Polypeptide
  • Male
  • Miotics / pharmacology
  • Peptide Fragments / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Reserpine / toxicity
  • Stomach Ulcer / chemically induced
  • Stomach Ulcer / drug therapy*

Substances

  • Amyloid
  • Anti-Ulcer Agents
  • Islet Amyloid Polypeptide
  • Miotics
  • Peptide Fragments
  • calcitonin gene-related peptide (8-37)
  • Reserpine
  • Calcitonin Gene-Related Peptide